- Trials with a EudraCT protocol (9)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
9 result(s) found for: Vinca alkaloids.
Displaying page 1 of 1.
EudraCT Number: 2005-003216-30 | Sponsor Protocol Number: 309544 | Start Date*: 2005-11-14 |
Sponsor Name:Schering AG | ||
Full Title: Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy, safety and tolerability of 4 regimes with 3 doses of ZK 219477 (16 and 12 mg/m² body ... | ||
Medical condition: Histologically proven metastatic breast cancer. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: DE (Completed) AT (Completed) ES (Completed) SI (Completed) IT (Completed) BE (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-000564-28 | Sponsor Protocol Number: MO18109 | Start Date*: 2004-11-01 |
Sponsor Name:F. Hoffmann-La Roche Ltd | ||
Full Title: An expanded access program of Tarceva (erlotinib) in patients with advanced stage IIIB/ IV non-small cell lung cancer (NSCLC) | ||
Medical condition: advanced stage IIIB/ IV non-small cell lung cancer (NSCLC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Completed) SK (Completed) SE (Completed) LV (Completed) AT (Completed) HU (Completed) LT (Completed) IE (Completed) CZ (Completed) IT (Prematurely Ended) BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-004499-38 | Sponsor Protocol Number: CCR 3116 | Start Date*: 2010-04-16 | |||||||||||
Sponsor Name:Royal Marsden NHS Foundation Trust | |||||||||||||
Full Title: A randomised double-blind placebo-controlled trial of the safety and efficacy of ethosuximide 250mg capsules for the management of chemotherapy-induced painful peripheral neuropathy. | |||||||||||||
Medical condition: The medicial condition under investigation is chemotherapy-induced painful peripheral neuropathy (CIPPN). CIPPN is a complication of several classes of chemotherapy agents e.g taxanes (paclitaxel, ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003080-45 | Sponsor Protocol Number: BRD/07/005 | Start Date*: 2008-07-11 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: Phase ll study evaluating the toxicity and efficacy of a modified German Paediatric Hodgkin's Lymphoma protocol (HD95) in young adults (aged 18-30 years) with Hodgkin's Lymphoma | |||||||||||||
Medical condition: Medical condition under investigation is known as Hodgkin's disease, which is a cancer of the lymphatic system. It is usually treated with either chemotherapy or radiotherapy or a combination of bo... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004032-21 | Sponsor Protocol Number: ARGX-113-2004 | Start Date*: 2021-05-07 | |||||||||||
Sponsor Name:argenx BV | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and the Safety of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immu... | |||||||||||||
Medical condition: Primary immune thrombocytopenia (ITP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) PT (Completed) DE (Completed) BG (Completed) NO (Completed) DK (Completed) GR (Completed) IT (Completed) FR (Completed) RO (Completed) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019987-35 | Sponsor Protocol Number: 20080435 | Start Date*: 2010-07-23 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A Phase 2, Interventional, Single Arm Study Describing Platelet Responses and ITP Remission Rates in Adult Subjects with Immune Thrombocytopenia Purpura Receiving Romiplostim. | |||||||||||||
Medical condition: Adult immune thrombocytopenic purpura (ITP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) DE (Completed) GB (Completed) ES (Completed) FR (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000245-13 | Sponsor Protocol Number: SOLTI-1907 | Start Date*: 2021-03-04 | |||||||||||
Sponsor Name:SOLTI | |||||||||||||
Full Title: A Phase II with 2 parallel cohorts clinical trial targeting estrogen receptor negative or PAM50 non-luminal disease with Atezolizumab in combination with Trastuzumab and Vinorelbine in HER2-positiv... | |||||||||||||
Medical condition: Pre- and post-menopausal women with locally advanced or metastatic HER2-positive breast cancer who have progressed to trastuzumab/pertuzumab and T-DM1. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002464-14 | Sponsor Protocol Number: GEIS-39 | Start Date*: 2017-03-02 |
Sponsor Name:Grupo Español de Investigación en Sarcomas (GEIS) | ||
Full Title: Phase II trial of nab-paclitaxel for the treatment of desmoid tumors and multiply relapsed/refractory desmoplastic small round cell tumors and Ewing sarcoma | ||
Medical condition: Cohort 1: Subjects with desmoid tumor Cohort 2: Subjects with desmoplastic small round cell tumor or Ewing sarcoma | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004095-31 | Sponsor Protocol Number: ModuLung | Start Date*: 2015-07-13 | |||||||||||||||||||||
Sponsor Name:Freistaat Bayer respresented by University of Regensburg represented by Kaufmännischer Direktor | |||||||||||||||||||||||
Full Title: A prospective phase II, randomized multi-center trial of a combined modularized treatment with metronomic low-dose treosulfan, pioglitazone and clarithromycin versus nivolumab in patients with squ... | |||||||||||||||||||||||
Medical condition: locally advanced or metastatic NSCLC, who have progressed during or following a platinum-containing regimen. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
